Chronic myeloid leukemia in children and adolescents: Results of treatment with imatinib mesylate

Leukemia and Lymphoma

Volumn 53, Issue 12, 2012, Pages 2430-2433

  Lakshmaiah, K C ^a   Bhise, Rohan ^a   Purohit, Samit ^a   Abraham, Linu J ^a   Lokanatha, D ^a   Suresh, T M ^a   Appaji, L ^a   Arunakumari, B S ^a   Govindbabu, K ^a  

^a KIDWAI MEMORIAL INSTITUTE OF ONCOLOGY   (India)

Author keywords

Adolescents; Children; Chronic myeloid leukemia; Imatinib

Indexed keywords

IMATINIB;

ADOLESCENT; ADULT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CHILD; CHILDHOOD CANCER; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CYTOGENETICS; EVENT FREE SURVIVAL; FOLLOW UP; HUMAN; OVERALL SURVIVAL; PRESCHOOL CHILD; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; SCHOOL CHILD;

ADOLESCENT; ANEMIA; ANTINEOPLASTIC AGENTS; CHILD; EXANTHEMA; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; NAUSEA; NEUTROPENIA; PIPERAZINES; PYRIMIDINES; REMISSION INDUCTION; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84868355760     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2012.694076     Document Type: Article

References (18)

1. Jabbour E, Kantarjian H. Introduction: chronic myelogenous leukemia (CML). Semin Hematol 2007;44(Suppl. 1):S1-S3.
2. Rowley JD. A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fl uorescence and Giemsa staining. Nature 1973;243:290-293.
3. Baccarani M, Cortes J, Pane F, et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 2009;27:6041-6051.
4. Druker BJ, Guilhot F, O' B rien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006;355:2408-2417. (Pubitemid 44903745)
5. Ries LAG, Smith MA, Gurney JG, et al. Cancer incidence and survival among children and adolescents: United States SEER Program 1975-1995. 1999. Available from: http://seer.cancer.gov/publications/childhood/
6. Champagne MA, Capdeville R, Krailo M, et al. Imatinib mesylate (STI571) for treatment of children with Philadelphia chromosomepositive leukemia: results from a Children's Oncology Group phase 1 study. Blood 2004;104:2655-2660. (Pubitemid 39434944)
7. Millot F, Guilhot J, Nelken B, et al. Imatinib mesylate is effective in children with chronic myelogenous leukemia in late chronic and advanced phase and in relapse after stem cell transplantation. Leukemia 2006;20:187-192. (Pubitemid 43148651)
8. Suttorp M, Millot F. Treatment of pediatric chronic myeloid leukemia in the year 2010: use of tyrosine kinase inhibitors and stemcell transplantation. Hematology Am Soc Hematol Educ Program 2010:368-376.
9. O' Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003;348:994-1004. (Pubitemid 36302244)
10. Baccarani M, Pane F, Saglio G. Monitoring treatment of chronic myeloid leukemia. Haematologica 2008;93:161-169.
11. Hughes T, Deininger M, Hochhaus A, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 2006;108:28-37. (Pubitemid 43990609)
12. Branford S, Fletcher L, Cross NC, et al. Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials. Blood 2008;112:3330-3338.
13. Mü ller MC, Erben P, Saglio G, et al. Harmonization of BCR-ABL mRNA quantification using a uniform multifunctional control plasmid in 37 international laboratories. Leukemia 2008;22:96-102.
14. Kantarjian HM, Deisseroth A, Kurzrock R, et al. Chronic myelogenous leukemia: a concise update. Blood 1993;82:691-703. (Pubitemid 23221645)
15. Millot F, Baruchel A, Guilhot J, et al. Imatinib is effective in children with previously untreated chronic myelogenous leukemia in early chronic phase: results of the French national phase IV trial. J Clin Oncol 2011;29:2827-2832.
16. El-Alfy MS, Al-Haddad AM, Hamed AA. Management of CML in the pediatric age group: imatinib mesylate or SCT. J Egypt Nat Cancer Inst 2010;22:227-232.
17. Champagne MA, Fu CH, Chang M, et al. Higher dose imatinib for children with de novo chronic phase chronic myelogenous leukemia: a report from the Children's Oncology Group. Pediatr Blood Cancer 2011;57:56-62.
18. Sokal JE, Cox EB, Baccarani M, et al. Prognostic discrimination in good-risk chronic granulocytic leukemia. Blood 1984;63:789-799. (Pubitemid 14141296)